RHABDOMYOSARCOMA

This study is testing a personalized peptide vaccine for children and young adults (up to age 30) with metastatic fusion-driven sarcomas (Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma) who have completed standard treatment. The vaccine is custom-made for each patient based on…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This study tests whether adding liposomal irinotecan to standard chemotherapy can help children with intermediate- or high-risk rhabdomyosarcoma live longer without their cancer returning. Participants receive different drug combinations based on their risk level, along with radi…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to bette…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This study tests whether giving targeted radiation to cancer that has spread (metastasized) can help children, teens, and young adults with sarcoma live longer. About 70 participants with soft tissue or bone sarcoma will receive consolidative radiation therapy to their metastatic…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This early-phase trial tests a new immunotherapy called CARE T cells in children and young adults with solid tumors that have returned or not responded to standard treatment. The cells are taken from the patient, genetically modified to recognize a protein (GPC3) found on many so…

This early-phase trial tests a new treatment for children and young adults with rhabdomyosarcoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better target cancer cells. Up to 50 partici…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then chec…

This study tests whether adding specially trained donor immune cells (NK cells) to standard chemotherapy can help children and young adults with sarcomas that have returned or not responded to treatment. About 50 participants aged 2 to 40 will receive up to 8 cycles of chemo plus…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study tests whether a green dye called indocyanine green (ICG) can help surgeons find sentinel lymph nodes—the first nodes where cancer might spread—in children with solid tumors. Ten children under 18 will get the dye injected during surgery, and doctors will check if it li…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…